The Cancer of the Pancreas Screening-5 (CAPS5) Study

Primary Outcome Measures:

• Evaluate pancreatic juice for early cancer markers. [ Time Frame: 8 years ] [ Designated as safety issue: No ]Aim #1: To evaluate pancreatic fluid mutations and circulating pancreatic epithelial cells as accurate markers of neoplasia by comparing their prevalence in cases with sporadic pancreatic neoplasia to healthy and disease controls.
  

Secondary Outcome Measures:

• Compare pancreas juice with pancreas cyst fluid [ Time Frame: 8 years ] [ Designated as safety issue: No ]Aim #2: To compare the prevalence of pancreatic fluid mutations and circulating pancreatic epithelial cells among a prospective cohort of individuals with sporadic pancreatic cysts undergoing pancreatic surveillance.
  

Other Outcome Measures:

• Time disease progression and prevalence [ Time Frame: 8 years ] [ Designated as safety issue: No ]Aim #3: To determine the prevalence of pancreatic lesions, pancreatic fluid mutations and circulating pancreatic epithelial cells among a large cohort of high-risk individuals undergoing pancreatic screening and surveillance of a new cohort in which screening is begun at age >55.

Inclusion Criteria:

• Hereditary Pancreatitis or
• Peutz-Jeghers Syndrome or
• Strong family history of pancreas cancer on one side of the family tree or
• Confirmed germline mutation carrier (BRCA2, FAMMM, PALB2, BRCA1, HNPCC, PRSS1/2, or CTRC
• Endoscopic evaluation of pancreas scheduled

Exclusion Criteria:

• Medical comorbidities or coagulopathy that contraindicate endoscopy
• Prior surgery that prevent optimal endoscopic ultrasound such as partial or complete gastrectomy with Bilroth or Roux-en-Y anastomosis
• Stricture or obstruction in the upper GI tract that does not allow passage of the echoendoscope
• Poor performance status
• Inability to provide informed consent
• Pregnancy